anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The number of women entering pregnancy with overweight or obesity is increasing. This can increase the risk for excessive gestational weight gain (GWG) which is associated with health complications for mother and baby. There are limited evidence-based interventions within antenatal care settings to encourage healthy eating and physical activity behaviours and support women with managing GWG.
METHODS: A previous habit-based intervention 'Ten Top Tips for a Healthy Weight' (10TT) was adapted and made suitable for pregnancy in line with the Medical Research Council's (MRC) complex intervention development guidelines. It involved three key activities: (1) identifying the evidence base; (2) identifying appropriate theory; and, (3) modelling processes. A core element was integrating lived experience via personal and public involvement (PPI).
RESULTS: The original 10TTs were adapted with PPI in line with current advice on nutrition and physical activity in pregnancy. New intervention materials were devised, including a leaflet and a logbook and app for self-monitoring to be delivered alongside a brief 1:1 conversation. Behaviour change techniques (BCTs) included in the new materials were coded using a number of behavioural taxonomies. An E-learning resource was created to help standardise the approach to delivery of the intervention and avoid stigmatising conversations.
CONCLUSION: Following MRC guidance for the development of complex interventions alongside significant PPI allowed for the adaption of 10TT habit-based weight management intervention into the 'Healthy Habits in Pregnancy and Beyond' (HHIPBe) intervention. The feasibility and acceptability of implementing this intervention in the antenatal setting will be explored in a feasibility randomised controlled trial.
TRIAL REGISTRATION: This study was registered on Clinical Trials as 'Healthy Habits in Pregnancy and Beyond (HHIPBe)' ClinicalTrials.gov Identifier: NCT04336878. The study was registered on 07/04/2020.
Altered ankyrin-R (AnkR; encoded by ANK1) expression is associated with diastolic function, left ventricular remodeling, and heart failure with preserved ejection fraction (HFpEF). First identified in erythrocytes, the role of AnkR in other tissues, particularly the heart, is less studied. Here, we identified the expression of both canonical and small isoforms of AnkR in the mouse myocardium. We demonstrate that cardiac myocytes primarily express small AnkR (sAnkR), whereas cardiac fibroblasts predominantly express canonical AnkR. As canonical AnkR expression in cardiac fibroblasts is unstudied, we focused on expression and localization in these cells. AnkR is expressed in both the perinuclear and cytoplasmic regions of fibroblasts with considerable overlap with the trans-Golgi network protein 38, TGN38, suggesting a potential role in trafficking. To study the role of AnkR in fibroblasts, we generated mice lacking AnkR in activated fibroblasts (Ank1-ifKO mice). Notably, Ank1-ifKO mice fibroblasts displayed reduced collagen compaction, supportive of a novel role of AnkR in normal fibroblast function. At the whole animal level, in response to a heart failure model, Ank1-ifKO mice displayed an increase in fibrosis and T-wave inversion compared with littermate controls, while preserving cardiac ejection fraction. Collagen type I fibers were decreased in the Ank1-ifKO mice, suggesting a novel function of AnkR in the maturation of collagen fibers. In summary, our findings illustrate the novel expression of AnkR in cardiac fibroblasts and a potential role in cardiac function in response to stress.
Stored data is accessed over a computer network through a network data manager. Data may be stored and transferred to the network data manager from a product device using an uploader application. In one aspect, a request message containing an access requestor identifier is received at the network data manager from a client device for access to a data storage facility. The network data manager determines if the access requestor identifier is associated with a data record that identifies a product device having a registration record, and if it does, the network data manager transmits a data link to the client device, wherein the data link provides access to the data record by the client device over the computer network for a predetermined time period such that access to the data record is halted upon expiration of the predetermined time period. The client device may comprise, for example, a desktop or laptop computer. The product device, for example, may comprise a portable insulin pump that can be connected to the computer for data transfer to and from the network data manager.
This subsequent program China Intracranial Aneurysm Project - 2 (CIAP-2) will comprise screening of 500 patients from the UIA cohort (CIAP-1) and focus on hemodynamics factors, high resolution magnetic resonance imaging (HRMRI), genetic factors and biomarkers. Possible risk factors for rupture of UIA, including genetic factors, biomarkers, HRMRI, and hemodynamic will be analyzed. The first project of the China Intracranial Aneurysm Project (CIAP-1: Chaired by the Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China) will establish a prospective cohort of 5000 patients with UIA from 20 centers in China, and collect baseline information for each patient. Multidimensional data will be acquired in follow-up assessments. Statistically significant clinical features in the UIA cohort will also be analyzed and integrated into this model for predicting risk of UIA rupture. After the model has been set up, the resultant evidence-based prediction will be used to provide a preliminary theoretical basis for the treatment of aneurysms at high risk of rupture.
<P>PROBLEM TO BE SOLVED: To provide a technology for referring to position information of examinee information together with an examinee image and allowing only a person having a right to view the examinee information on the basis of the position information.  <P>SOLUTION: An image diagnosis device, an information management device for managing the examinee information, and a display device are arranged under the environment where they can acquire information from one another. The image diagnosis device acquires the position information indicating a storage area of the examinee information to combine it with the examinee information. The display device stores identification information in advance, accesses the storage area indicated by the position information, and transmits the identification information. The information management device determines on the basis of the identification information whether or not log-in is permitted and determines a right of access to the storage area to be accessed. When the log-in is permitted and the right of access is approved, the examinee information stored in the storage area is transmitted to the display device. The display device receives information to be transmitted from the information management device and displays it.  <P>COPYRIGHT: (C)2007,JPO&INPIT
This is a Phase IV study cohort, uncontrolled, composed of two segments: children and healthy adults. It will be included 2756 children and 2005 adults, evaluated initially in six different times (before vaccination, 30-45 days, 1 year, 4 years, 7 years and 10 years after vaccination). The Paraiba state was selected for the study because in this region there are no yellow fever virus dissemination and therefore no NIP recommendation for people's routine vaccination. However, the NIP indicate yellow fever vaccination for individuals who are moving to areas with virus circulation. The study will take place in six (6) Basic Health Units of three (3) municipalities (2 units per municipality) in the state of Paraíba. The selected municipalities are: Alhandra, Caaporã and Conde. The study target population consisted of healthy children and adults of both sexes. Children must be between 9 months and 4 years,11months and 29 days; adults between 18 and 50 years. It will be eligible for the study, people who have never received the yellow fever vaccine checked in vaccine design and history and who agree to participate. Not be included participants with any contraindication to vaccination against yellow fever and individuals who previously moved to risk areas for extended periods.
A labor management system wherein first data indicates the result for each first item constituting a first group of items. The first data indicates the result for each first item for an employee as a history. Second data indicates the result for each second item constituting a second group of items. The second data indicates the result for each second item for the employee. An input unit receives, as inputs, at least one first item and at least one second item, as specification items. An output control unit controls outputs to an output unit such that the output unit outputs a graph showing the results for each specification item. The graph includes the first data and the second data. The position of the result for each specification item on a time axis is aligned with the position of the results for the other specification items.
In this arm patients will receive ketamine 1-2 mg/kg IV slow as a systemic analgesia. ketamine as a PCP derivative has both hypnotic and analgesic effects.
1. A pharmaceutical composition consisting essentially of a dialysis solution containing ferric pyrophosphate deluted in a dialysis solution. 2. A composition according to any of claim 1 wherein the dialysis solution is a bicarbonate-based dialysis solution. 3. A composition according to any of claim 1 or 2 wherein the dialysis solution is an acetate-based dialysis solution. 4. A composition according to any preceding claim wherein the dialysis solution is for hemodialysis and contains from 2 to 50 micrograms of iron per decilitre of dialysis solution. 5. A composition according to any of claims 1-4 wherein the dialysis solution is for peritoneal dialysis and contains up to 500 micrograms of iron per decilitre of dialysis solution. 6. A method of iron administration during dialysis to a patient including administering a dialysis solution to a patient according to any of the preceding claims. 7. A method of modifying hematologic parameters by transfer of ferric pyrophosphate from the dialysis solution to the blood compartment during the process of dialysis, wherein said dialysis solution is a composition according to any of claims 1 to 5. 8. A pharmaceutical composition of ferric pyrophosphate soluable in a dialysis solution, suitable for preparing a composition according to any of claims 1 to 5.
Nylon coated microcapsules containing hydrophilic solvent-soluble anionic, cationic or quaternary drug salts were prepared by interfacial polycondensation techniques. In a first stage, the drug substance to be encapsulated is dissolved in an aqueous phase. Examples of drugs encapsulated are morphine sulfate, diphenhydramine hydrochloride, and methantheline bromide. Next the aqueous drug solution is dispersed in an organic phase. In a second stage complementary polycondensation reactants each in an organic phase are added separately, either sequentially or simultaneously, to the dispersion prepared in the first stage. Microcapsules of nylon form around the hydrophilic solvent soluble core drug substance.
Propranolol should be used with caution in patients with impaired hepatic or renal function. Propranolol hydrochloride tablets are not indicated for the treatment of hypertensive emergencies.

Beta-adrenergic receptor blockade can cause reduction of intraocular pressure. Patients should be told that propranolol hydrochloride may interfere with the glaucoma screening test. Withdrawal may lead to a return of increased intraocular pressure.

While taking beta blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction.
But the oral liquid of special invention and release sweating and expelling toxin is called for short the sweating and expelling toxin oral liquid.Its composition and partition: 1.9 one-tenth of sucrose sugar, 0.4 one-tenth in Rhizoma Zingiberis Recens, 0.2 one-tenth of chilli, 0.2 one-tenth in Fructus Piperis, 0.5 one-tenth in Herba Alii fistulosi, 7 one-tenth of drinking waters, as the saying goes, general rule is not bitterly, and is bitterly then obstructed.Catching a cold mostly is because blood capillary stops up, and causes the headache fever, feeble.But this oral liquid is bacteriostasis and sterilization both, can force antiperspirant to urge antiperspirant again, and it is taken, and is very natural, makes the unimpeded and discharge toxin of blood capillary, so get well soon.Can regard special beverage at ordinary times.Long-term drink also has such benefit: 1. improve digestive system, people's appetite is heightened.2. eliminate by aching all over that rheumatism causes relaxation and happiness after the dysphoria at first.Sum up its advantage: 1. production process is simple.2. cost hangs down the profit height.3. effect is remarkable.4. taste peppery sweet matching.5. be free from side effects.6. not perishable.7, demand is big.Be suitable for numerous personages.8. but not only can cure the disease but also body-building, make the best of both worlds.To the significant of this project, should develop energetically, produce for a long time.
A method for obtaining an immunogenic strain useful for producing a vaccine against Coccidiosis comprises the cycle of infecting at least one first group of specific pathogen-free donor birds with oocysts from an Eimeria species. Blood is then collected from these donor birds, and is then used to infect a second group of specific pathogen-free birds. Oocysts are collected from the second group of birds. These oocysts are then multiplicated to complete the cycle. The cycle is then repeated using the multiplicated oocysts. After a total of about three cycles, a final antigen may be harvested and utilized as a source to generate oocysts for a vaccine.
The fluid management algorithm of the control group is based on the standard care procedure of our ICU as recommended in guidelines: the patient's fluid status is assessed by performing a fluid challenge with a bolus of 250 ml colloids. When the patients is fluid responsive (i.e. showing an increase in stroke volume \> 10% ) he will receive an additional bolus of 250 ml of colloids. After each fluid challenge, patients will be revaluated for fluid responsiveness to access need of further fluid administration.
Post-transcriptional regulation of immune-related transcripts by RNA-binding proteins (RBPs) impacts immune cell responses, including mast cell functionality. Despite their importance in immune regulation, the functional role of most RBPs remains to be understood. By manipulating the expression of specific RBPs in murine mast cells, coupled with mass spectrometry and transcriptomic analyses, we found that the Regnase family of proteins acts as a potent regulator of mast cell physiology. Specifically, Regnase-1 is required to maintain basic cell proliferation and survival, whereas both Regnase-1 and -3 cooperatively regulate the expression of inflammatory transcripts upon activation, with Tnf being a primary target in both human and mouse cells. Furthermore, Regnase-3 directly interacts with Regnase-1 in mast cells and is necessary to restrain Regnase-1 expression through the destabilization of its transcript. Overall, our study identifies protein interactors of endogenously expressed Regnase factors, characterizes the regulatory interplay between Regnase family members in mast cells, and establishes their role in the control of mast cell homeostasis and inflammatory responses.
The prognosis of sarcoma patients in stage IV is poor. For STS, the response rate of chemotherapy is only 20-35% and the median survival time is about 12 months. The 5 year survival rate is lower than 10% reported in several large-scale studies. Although chemotherapy plays a major role in the treatment of advanced STS, the classic chemotherapy agents are not curative. Combination chemotherapy or dose-dense regimens have largely failed to improve the response rates. Long-term using of cytotoxic drugs increased the risk of toxicity in patients. Apatinib is a small molecular inhibitor of Vascular Epithelial Growth Factor Receptor-2 (VEGFR-2). It has been approved as a second-line treatment for advanced gastric cancer. Several phase III clinical studies of non small cell lung cancer, liver cancer, colorectal cancer and other tumors also showed apatinib has less toxic side effects and better patient tolerance. However, the clinical application of apatinib in STS is still lack of evidence-based medicine. And this clinical trial is designed to prospectively investigate the efficacy and safety of apatinib in stage IV sarcoma patients who failed in chemotherapy.
Teratogenic Effects: Pregnancy Category C

Rat fetuses of dams administered verteporfin for injection intravenously at ≥10 mg/kg/day during organogenesis (approximately 40-fold human exposure at 6 mg/m2 based on AUCinf in female rats) exhibited an increase in the incidence of anophthalmia/microphthalmia. Rat fetuses of dams administered 25 mg/kg/day (approximately 125 fold the human exposure at 6 mg/m2 based on AUCinf in female rats) had an increased incidence of wavy ribs and anophthalmia/microphthalmia.

In pregnant rabbits, a decrease in body weight gain and food consumption was observed in animals that received verteporfin for injection intravenously at ≥10 mg/kg/day during organogenesis. The no observed adverse effect level (NOAEL) for maternal toxicity was 3 mg/kg/day (approximately 7-fold human exposure at 6 mg/m2 based on body surface area). There were no teratogenic effects observed in rabbits at doses up to 10 mg/kg/day.

There are no adequate and well-controlled studies in pregnant women. Visudyne should be used during pregnancy only if the benefit justifies the potential risk to the fetus.
Approximately 150 will be non-AD controls (including approximately 50 children, 6-17 years of age, and 100 adults, = 18 years of age) Non-AD control participants will apply Vanicream™ beginning at Day 0 through Day 7. Non-AD control participants will return for assessment visits at Day 35, 91, and 140. At Day 140, participants will resume application of Vanicream™ through the End of Study Assessment (Day 168).
A soap-free shaving and moisturizing composition which maintains superior performance attributes while avoiding the harshness and drying associated with soap-based shave preparations is described. The shaving and moisturizing composition preferably comprises deionized water, a humectant, a water-based silicone lubricant, and sodium hyaluronate. The composition can also contain a conditioner, preservatives, allantoin, and various heavy alkaloid extracts. The present invention is a single shaving composition that performs as a shave cream, an after shave, and a moisturizer. Applying the composition does not require the application of water on the shave area or that water be added to the shaving composition, however water can be applied if desired. In addition, use of the shaving composition does not require a hydration wait time between applying the composition and shaving. Once shaving is complete, any residual shaving composition on the shaved area is rubbed into the skin and acts as an after shave and a long-term moisturizer. Shaving can be performed by using a multiple blade razor having an open flow design, thereby reducing resistance while shaving and decreasing dryness and irritation of the skin.
This is a blinded study to be conducted at San Diego Sexual Medicine in San Diego, CA. Participants meeting inclusion and exclusion criteria will receive one treatment cycle of active treatment or sham. The device will be equipped with 3 protocols in addition to the standard protocol, two of which are identical to the standard protocol (for active treatment) and one of which does not deliver HIFEM (for sham treatment). The active treatment arm consists of 6 treatments, 2 per week, with at least one day in between. Follow-up visits will occur at 4 weeks and 12 weeks after the last treatment. Unblinding will take place at the 12 week follow up visit, and subjects assigned to the sham arm will be crossed over to active treatment, beginning their first treatment on that day, completing 6 treatments and 2 follow up visits. Once unblinded the subject will be treated with the standard protocol of the device.

After the informed consent is signed, and inclusion and exclusion criteria completed, participants will complete validated questionnaires and undergo a baseline physical therapy assessment of pelvic floor muscle strength.
This study aimed to determine the effects of seasons on the diversity and dynamics of insects associated with pig carrion in Gampela, Plateau Central Region, Burkina Faso, West Africa. Pig carcasses (Sus scrofa domesticus L.) were exposed in an open area to monitor their decomposition process and their colonization by insects during a warm and dry period (March-April 2015), a warm and wet period (August-September 2015) and a cool and dry period (December 2015-January 2016). Monitoring and entomological data collection occurred for 60 days for each study period. The decomposition process always included five stages (fresh, bloating, putrefaction, postputrefaction, and skeletal), which varied in duration depending on the study period. In sum, 118,761 insects belonging to 4 orders, 12 families, 17 genera, and 21 species were collected during the three study periods, with approximately 61% of the individuals collected during the warm and wet period. The dynamics of insect populations associated with the pig carcasses included two peaks at each study period. Formicidae was the most abundant insect family in each study period, but Musca domestica was the most abundant species. The listed species were found to belong to four trophic groups with a predominance of predators/carnivores followed by necrophagous insects. The orders, families, and trophic groups reported in this study were significantly more abundant during the warm and wet period. The results show prospects for the use of Calliphoridae, Muscidae, and Dermestidae in criminal investigations, depending on seasonal variations in Sudano-Sahelian areas.
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of isatuximab-irfc or of other isatuximab products.

Overall, across 9 clinical studies in relapsed and/or refractory multiple myeloma (RRMM) with SARCLISA single-agent and combination therapies including ICARIA-MM and IKEMA (N=1023), the incidence of treatment emergent anti-drug antibodies (ADAs) was <2%. In ICARIA-MM and IKEMA, no patients with RRMM tested positive for ADA. Therefore, the neutralizing ADA status was not determined. In RRMM, no effect of ADAs was observed on the pharmacokinetics, safety, or efficacy of SARCLISA. 

In IMROZ, out of the 263 patients with NDMM treated with SARCLISA in combination with bortezomib, lenalidomide, and dexamethasone, 253 were evaluable for the presence of ADA, 22 patients (8.7%) tested positive for treatment-emergent ADAs, with 21 patients considered to have a transient ADA response and 1 considered to have an indeterminate ADA response. Among these 22 ADA-positive patients, 13 (5.9%) had neutralizing antibodies. In IMROZ, a trend to lower exposure was observed in ADA-positive patients, which was considered not clinically relevant. In patients with ADA-positive status to SARCLISA, including those with neutralizing antibodies, no meaningful impact of ADAs on safety or efficacy of SARCLISA was observed.